Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: lørdag 16. desember
Oversikt
Kursliste
Indekser
Nyheter
Største handler
Tegningsretter
Historikk
Vinnere/tapere
Høy/lav

15/11-2017 13:36:45: (NANO) Nordic Nanovector ASA - Financial Calendar

Oslo, Norway, 15th of November 2017

FINANCIAL YEAR 2017

Quarterly Report - Q3  22.11.2017

Quarterly Report - Q4  27.02.2018

Capital Markets Day    22.11.2017

FINANCIAL YEAR 2018

Quarterly Report - Q1  30.05.2018

Half-yearly Report       22.08.2018

Quarterly Report - Q3  21.11.2018

The dates are subject to change. The time and location of the presentations will
be announced in due time.

This information is published pursuant to the requirements set out in the
Continuing obligations.

For further information, please contact:

IR enquiries: Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76

Email: ir@nordicnanovector.com

Media enquiries: Mark Swallow/David Dible/Marine Perrier (Citigate Dewe
Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedr.co.uk

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugate (ARC)
designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly
develop Betalutin®, alone and in combination with other therapies, for the
treatment of major types of NHL, targeting first regulatory submission in
relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to
retain marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and
other immunotherapies for multiple cancer indications.

Further information about the Company can be found at www.nordi

Ekstern link: http://www.newsweb.no/index.jsp?messageId=438735

Nyheten er levert av OBI.

Utforming |  Hjelp |  Utskrift  | Bytt til sanntid Ingen åpne markeder
lørdag 16/12-2017 21:52:26